Sign In
Buy NMRA
$1.61
+0.0100 (+0.625%)
At Close: Aug 05, 2026
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
11:22am, Monday, 30'th Mar 2026
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
06:53am, Monday, 30'th Mar 2026
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
07:27pm, Thursday, 19'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
07:00am, Monday, 16'th Mar 2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
02:32pm, Tuesday, 17'th Feb 2026
NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.
Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026
01:02am, Monday, 16'th Feb 2026
Neumora Therapeutics (NASDAQ: NMRA) executives highlighted new clinical-scale analyses for NMRA-511 in Alzheimer's disease (AD) agitation and reviewed pipeline milestones during a presentation at the
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts
04:14am, Friday, 06'th Feb 2026
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) has earned an average recommendation of "Hold" from the eleven research firms that are presently covering the firm, MarketBeat Ratings repor
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Wednesday, 04'th Feb 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targe
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Hold” from Brokerages
02:10am, Monday, 12'th Jan 2026
Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) have been given an average rating of "Hold" by the ten analysts that are presently covering the stock, MarketBeat.com reports. Thr
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses
04:32am, Tuesday, 06'th Jan 2026
Neumora Therapeutics (NASDAQ: NMRA) reported top-line results from a Phase IB signal-seeking study of NMRA-511 in agitation associated with dementia due to Alzheimer's disease, with management highlig
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
01:28pm, Monday, 05'th Jan 2026
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
06:35am, Monday, 05'th Jan 2026
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to co
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation
06:30am, Monday, 05'th Jan 2026
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-speci
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
03:30am, Saturday, 20'th Dec 2025
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast t
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
01:45pm, Monday, 01'st Dec 2025
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.
